Patient Gateway

RSS Feed

BeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLC

Tumor-associated macrophages beyond M1/M2 in NSCLC: spatially organized programs, therapy resistance, and translational targeting

汤传昊教授：HER2 变异 NSCLC 关键研究盘点与临床决策启示

KEYNOTE-671: Perioperative Pembrolizumab Redefines Curative-Intent Therapy in Resectable NSCLC

Impact of post-resistance molecular retesting strategies on treatment timeliness and clinical outcomes in EGFR-mutant advanced NSCLC: a real-world study

Switching to SC Dosing and Considering PRO Data for Amivantamab in NSCLC

毕楠教授深度解读ADVANCE研究：“去化疗”方案有望成为EGFR突变III期不可切NSCLC治疗新范式_腾讯新闻